• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.ω-3 脂肪酸治疗非酒精性脂肪性肝病。
World J Gastroenterol. 2012 Nov 7;18(41):5839-47. doi: 10.3748/wjg.v18.i41.5839.
2
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.n-3 多不饱和脂肪酸治疗酒精性肝病:批判性评价。
Crit Rev Food Sci Nutr. 2019;59(sup1):S116-S129. doi: 10.1080/10408398.2018.1544542. Epub 2018 Dec 22.
3
Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids.非酒精性脂肪性肝病及其 n-3 多不饱和脂肪酸治疗。
Clin Nutr. 2018 Feb;37(1):37-55. doi: 10.1016/j.clnu.2017.01.006. Epub 2017 Jan 19.
4
Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.ω-3 脂肪酸与非酒精性脂肪性肝病:疗效证据与作用机制。
Mol Aspects Med. 2018 Dec;64:135-146. doi: 10.1016/j.mam.2018.03.001. Epub 2018 Mar 22.
5
N-3 polyunsaturated fatty acids ameliorate hepatic steatosis via the PPAR-α/CPT-1α pathway in a mouse model of parenteral nutrition.N-3 多不饱和脂肪酸通过 PPAR-α/CPT-1α 通路改善肠外营养小鼠模型的肝脂肪变性。
Biochem Biophys Res Commun. 2018 Jul 2;501(4):974-981. doi: 10.1016/j.bbrc.2018.05.095. Epub 2018 May 21.
6
The Ameliorating Effects of n-3 Polyunsaturated Fatty Acids on Liver Steatosis Induced by a High-Fat Methionine Choline-Deficient Diet in Mice.n-3 多不饱和脂肪酸对高脂肪蛋氨酸胆碱缺乏饮食诱导的小鼠肝脂肪变性的改善作用。
Int J Mol Sci. 2023 Dec 7;24(24):17226. doi: 10.3390/ijms242417226.
7
Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.ω-3 脂肪酸治疗儿童非酒精性脂肪性肝病:系统评价和随机对照试验的荟萃分析。
Clin Nutr. 2018 Apr;37(2):516-521. doi: 10.1016/j.clnu.2016.12.009. Epub 2016 Dec 23.
8
Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).氧化苦参碱通过抑制固醇调节元件结合转录因子 1(Srebf1)和激活过氧化物酶体增殖物激活受体 α(Pparα),减轻高果糖饮食诱导的非酒精性脂肪性肝病大鼠的肝脂肪变性。
Eur J Pharmacol. 2013 Aug 15;714(1-3):89-95. doi: 10.1016/j.ejphar.2013.06.013. Epub 2013 Jun 18.
9
Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.ω-3多不饱和脂肪酸治疗非酒精性脂肪性肝炎:一项随机、双盲、安慰剂对照试验
Clin Nutr. 2016 Jun;35(3):578-86. doi: 10.1016/j.clnu.2015.05.001. Epub 2015 May 21.
10
n-3 Fatty acids combined with flavan-3-ols prevent steatosis and liver injury in a murine model of NAFLD.n-3 脂肪酸与黄烷-3-醇联合预防 NAFLD 小鼠模型的脂肪变性和肝损伤。
Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):69-78. doi: 10.1016/j.bbadis.2017.10.002. Epub 2017 Oct 3.

引用本文的文献

1
Unraveling the Association Between Cheese Consumption and Non-Alcoholic Fatty Liver Disease: Insights From a Two-Sample Mendelian Randomization Analysis.解析奶酪消费与非酒精性脂肪性肝病之间的关联:来自两样本孟德尔随机化分析的见解
Food Sci Nutr. 2025 May 10;13(5):e70213. doi: 10.1002/fsn3.70213. eCollection 2025 May.
2
The effect of healthy eating index-2015 in the associations of biological aging and non-alcoholic fatty liver disease: an interaction and mediation analysis.2015年健康饮食指数在生物衰老与非酒精性脂肪性肝病关联中的作用:交互作用与中介分析
J Health Popul Nutr. 2025 Jan 24;44(1):18. doi: 10.1186/s41043-025-00755-z.
3
G-Protein-Coupled Receptor 120 Agonist Mitigates Steatotic and Fibrotic Features Triggered in Obese Mice by the Administration of a High-Fat and High-Carbohydrate Diet.G蛋白偶联受体120激动剂减轻高脂高碳水化合物饮食诱导的肥胖小鼠的脂肪变性和纤维化特征。
ACS Omega. 2024 Jul 10;9(29):31899-31909. doi: 10.1021/acsomega.4c03507. eCollection 2024 Jul 23.
4
Mapping global research trends: Nutrition associations with nonalcoholic fatty liver disease - a Scopus bibliometric analysis.绘制全球研究趋势图:营养与非酒精性脂肪性肝病的关联——Scopus 文献计量分析。
World J Gastroenterol. 2024 Jun 28;30(24):3106-3119. doi: 10.3748/wjg.v30.i24.3106.
5
The Ameliorating Effects of n-3 Polyunsaturated Fatty Acids on Liver Steatosis Induced by a High-Fat Methionine Choline-Deficient Diet in Mice.n-3 多不饱和脂肪酸对高脂肪蛋氨酸胆碱缺乏饮食诱导的小鼠肝脂肪变性的改善作用。
Int J Mol Sci. 2023 Dec 7;24(24):17226. doi: 10.3390/ijms242417226.
6
The interplay between dietary fatty acids and gut microbiota influences host metabolism and hepatic steatosis.膳食脂肪酸与肠道微生物群的相互作用影响宿主代谢和肝脂肪变性。
Nat Commun. 2023 Sep 1;14(1):5329. doi: 10.1038/s41467-023-41074-3.
7
Identification of polyunsaturated fatty acids related key modules and genes in metabolic dysfunction-associated fatty liver disease using WGCNA analysis.使用加权基因共表达网络分析(WGCNA)鉴定代谢功能障碍相关脂肪性肝病中多不饱和脂肪酸相关的关键模块和基因。
Front Genet. 2022 Nov 8;13:951224. doi: 10.3389/fgene.2022.951224. eCollection 2022.
8
The first study on the effect of crocodile oil from on hepatic mitochondrial function for energy homeostasis in rats.关于来自[具体来源未明确]的鳄鱼油对大鼠肝脏线粒体功能以维持能量稳态影响的第一项研究。
Vet World. 2022 Apr;15(4):986-997. doi: 10.14202/vetworld.2022.986-997. Epub 2022 Apr 19.
9
The association between major dietary patterns with the risk of non-alcoholic fatty liver disease, oxidative stress and metabolic parameters: A case-control study.主要饮食模式与非酒精性脂肪性肝病风险、氧化应激及代谢参数之间的关联:一项病例对照研究。
J Diabetes Metab Disord. 2022 Mar 19;21(1):657-667. doi: 10.1007/s40200-022-01028-w. eCollection 2022 Jun.
10
Nanocarriers for Drug Delivery: An Overview with Emphasis on Vitamin D and K Transportation.用于药物递送的纳米载体:重点关注维生素D和K转运的概述
Nanomaterials (Basel). 2022 Apr 17;12(8):1376. doi: 10.3390/nano12081376.

本文引用的文献

1
Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.接受肿瘤坏死因子-α 阻滞剂治疗的银屑病关节炎患者的肝脂肪变性和疾病活动度。
J Rheumatol. 2012 May;39(5):1042-6. doi: 10.3899/jrheum.111391. Epub 2012 Mar 15.
2
The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals.Scap/SREBP 通路对于动物的糖尿病性脂肪肝和碳水化合物诱导的高甘油三酯血症的发展是必不可少的。
Cell Metab. 2012 Feb 8;15(2):240-6. doi: 10.1016/j.cmet.2011.12.017.
3
Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.非酒精性脂肪肝疾病与美国人群中心血管疾病之间的独立相关性。
Clin Gastroenterol Hepatol. 2012 Jun;10(6):646-50. doi: 10.1016/j.cgh.2011.12.039. Epub 2012 Jan 13.
4
Omega-3 fatty acids enhance mitochondrial superoxide dismutase activity in rat organs during post-natal development.ω-3 脂肪酸可增强发育期大鼠各器官中线粒体超氧化物歧化酶的活性。
Int J Biochem Cell Biol. 2012 Jan;44(1):123-31. doi: 10.1016/j.biocel.2011.10.007. Epub 2011 Oct 30.
5
Mediterranean diet in healthy lifestyle and prevention of stroke.地中海饮食与健康生活方式及中风预防
Acta Clin Croat. 2011 Mar;50(1):67-77.
6
Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中脂肪变性的分子机制
Nutr Hosp. 2011 May-Jun;26(3):441-50. doi: 10.1590/S0212-16112011000300003.
7
Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets.肝内 n-3 多不饱和脂肪酸耗竭促进小鼠脂肪变性和胰岛素抵抗:细胞靶点的基因组分析。
PLoS One. 2011;6(8):e23365. doi: 10.1371/journal.pone.0023365. Epub 2011 Aug 10.
8
Omega-3 fatty acids reduce hepatic steatosis and consequently attenuate ischemia-reperfusion injury following partial hepatectomy in rats.ω-3 脂肪酸可减少肝脏脂肪变性,从而减轻大鼠部分肝切除术后的缺血再灌注损伤。
Dig Liver Dis. 2011 Dec;43(12):984-90. doi: 10.1016/j.dld.2011.07.009. Epub 2011 Aug 12.
9
Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.二十二碳六烯酸补充剂可降低非酒精性脂肪性肝病患儿的肝内脂肪含量:双盲随机对照临床试验。
Arch Dis Child. 2011 Apr;96(4):350-3. doi: 10.1136/adc.2010.192401. Epub 2011 Jan 12.
10
High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism.特发性静脉血栓栓塞患者中非酒精性脂肪肝的高患病率。
World J Gastroenterol. 2010 Dec 28;16(48):6119-22. doi: 10.3748/wjg.v16.i48.6119.

ω-3 脂肪酸治疗非酒精性脂肪性肝病。

Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.

机构信息

Department of Clinical and Experimental Medicine, Regional Reference Centre for Coagulation Disorders, "Federico II" University, 80131 Naples, Italy.

出版信息

World J Gastroenterol. 2012 Nov 7;18(41):5839-47. doi: 10.3748/wjg.v18.i41.5839.

DOI:10.3748/wjg.v18.i41.5839
PMID:23139599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3491590/
Abstract

Non-alcoholic fatty liver disease (NAFLD) has been recognized as a major health burden. It is the most important cause of chronic liver disease and a major independent cardiovascular risk factor. Lacking a definite treatment for NAFLD, a specific diet and an increase in physical activity represent the most commonly used therapeutic approaches. In this review, major literature data about the use of omega-3 polyunsaturated fatty acids (n-3 PUFAs) as a potential treatment of NAFLD have been described. n-3 PUFAs, besides having a beneficial impact on most of the cardio-metabolic risk factors (hypertension, hyperlipidemia, endothelial dysfunction and atherosclerosis) by regulating gene transcription factors [i.e., peroxisome proliferator-activated receptor (PPAR) α, PPARγ, sterol regulatory element-binding protein-1, carbohydrate responsive element-binding protein], impacts both lipid metabolism and on insulin sensitivity. In addition to an enhancement of hepatic beta oxidation and a decrease of the endogenous lipid production, n-3 PUFAs are able to determine a significant reduction of the expression of pro-inflammatory molecules (tumor necrosis factor-α and interleukin-6) and of oxygen reactive species. Further strengthening the results of the in vitro studies, both animal models and human intervention trials, showed a beneficial effect of n-3 PUFAs on the severity of NAFLD as expressed by laboratory parameters and imaging measurements. Despite available results provided encouraging data about the efficacy of n-3 PUFAs as a treatment of NAFLD in humans, well-designed randomized controlled trials of adequate size and duration, with histological endpoints, are needed to assess the long-term safety and efficacy of PUFA, as well as other therapies, for the treatment of NAFLD and non-alcoholic steatohepatitis patients. It is worthwhile to consider that n-3 PUFAs cannot be synthesized by the human body and must be derived from exogenous sources (fish oil, flaxseeds, olive oil) which are typical foods of the Mediterranean diet, known for its beneficial effects in preventing obesity, diabetes and, in turn, cardiovascular events. According to these data, it is important to consider that most of the beneficial effects of n-3 PUFAs can also be obtained by an equilibrate nutrition program.

摘要

非酒精性脂肪性肝病(NAFLD)已被认为是一个主要的健康负担。它是慢性肝病的最重要原因,也是心血管疾病的一个主要独立危险因素。由于缺乏对 NAFLD 的明确治疗方法,特定的饮食和增加身体活动是最常用的治疗方法。在这篇综述中,描述了关于使用ω-3 多不饱和脂肪酸(n-3 PUFAs)作为 NAFLD 潜在治疗方法的主要文献数据。n-3 PUFAs 通过调节基因转录因子(即过氧化物酶体增殖物激活受体(PPAR)α、PPARγ、固醇调节元件结合蛋白-1、碳水化合物反应元件结合蛋白),对大多数心血管代谢危险因素(高血压、高血脂、内皮功能障碍和动脉粥样硬化)产生有益影响,同时影响脂质代谢和胰岛素敏感性。除了增强肝β氧化和减少内源性脂质产生外,n-3 PUFAs 还能够显著降低促炎分子(肿瘤坏死因子-α和白细胞介素-6)和氧反应性物质的表达。进一步加强体外研究的结果,动物模型和人体干预试验都表明,n-3 PUFAs 对 NAFLD 的严重程度有有益的影响,这可以通过实验室参数和影像学测量来表达。尽管现有的结果提供了关于 n-3 PUFAs 作为人类 NAFLD 治疗的有效性的令人鼓舞的数据,但需要设计适当大小和持续时间的、具有组织学终点的、随机对照试验,以评估 PUFA 以及其他治疗方法治疗 NAFLD 和非酒精性脂肪性肝炎患者的长期安全性和有效性。值得考虑的是,人体不能合成 n-3 PUFAs,必须从外源性来源(鱼油、亚麻籽、橄榄油)中获得,这些都是地中海饮食的典型食物,因其在预防肥胖、糖尿病和进而预防心血管事件方面的有益作用而闻名。根据这些数据,重要的是要考虑到 n-3 PUFAs 的大部分有益作用也可以通过均衡的营养计划来获得。